

## H.R. 1076, Preventing the Financing of Illegal Synthetic Drugs Act

As ordered reported by the House Committee on Financial Services on February 28, 2023

By Fiscal Year, Millions of Dollars	2023	2023-2028	2023-2033
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Increase or Decrease (-) in the Deficit	0	0	0
Spending Subject to Appropriation (Outlays)	*	*	not estimated
Increases <i>net direct spending</i> in any of the four consecutive 10-year periods beginning in 2034?	No	Statutory pay-as-you-go procedures apply?	No
		<b>Mandate Effects</b>	
Increases <i>on-budget deficits</i> in any of the four consecutive 10-year periods beginning in 2034?	No	Contains intergovernmental mandate?	No
		Contains private-sector mandate?	No
* = between zero and \$500,000.			

H.R. 1076 would require the Government Accountability Office (GAO) to study the illicit financing of synthetic-drug trafficking and the federal government’s efforts to combat those activities. The bill would require the GAO to report its findings to the Congress within one year of enactment.

Based on the cost to produce similar reports, CBO estimates that implementing H.R. 1076 would cost less than \$500,000 over the 2023-2028 period; any such spending would be subject to the availability of appropriated funds.

The CBO staff contact for this estimate is Jeremy Crimm. The estimate was reviewed by Chad Chirico, Deputy Director of Budget Analysis.



Phillip L. Swagel  
Director, Congressional Budget Office